Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease

Background: Phosphorylated tau (p-tau) epitopes in cerebrospinal fluid (CSF) are accurate biomarkers for a pathological and clinical diagnosis of Alzheimer's disease (AD) and are seen to be increased in preclinical stage of the disease. However, it is unknown if these increases transpire earlie...

ver descrição completa

Detalhes bibliográficos
Autor principal: Ashton, Nicholas J. (author)
Outros Autores: Benedet, Andréa L. (author), Pascoal, Tharick Ali (author), Karikari, Thomas K. (author), Lantero-Rodriguez, Juan (author), Brum, Wagner Scheeren (author), Mathotaarachchi, Sulantha Sanjeewa (author), Therriault, Joseph (author), Savard, Mélissa (author), Chamoun, Mira (author), Stoops, Erik (author), François, Cindy (author), Vanmechelen, Eugeen (author), Gauthier, Serge (author), Zimmer, Eduardo Rigon (author), Zetterberg, Henrik (author), Blennow, Kaj (author), Rosa Neto, Pedro (author)
Formato: other article
Idioma:eng
Publicado em: 2022
Assuntos:
Líquido cefalorraquidiano
Doença de Alzheimer
Proteínas tau
Peptídeos beta-amilóides
Tomografia por emissão de pósitrons
Biomarcadores
Cerebrospinal fluid
Phosphorylated tau
Alzheimer’s disease
Preclinical
Amyloid
Positron emission tomography
Texto completo:http://hdl.handle.net/10183/239847
País:Brasil
Oai:oai:www.lume.ufrgs.br:10183/239847

Texto Completo

http://hdl.handle.net/10183/239847

Registos relacionados